Table 4.
Predictive factors for the overall survival of patients with unresectable pancreatic cancer (univariate and multivariate logistic regression analyses).
| Variables | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p-Value | HR | 95%CI | p-Value | |
| Age (per year) | 0.67 | - | 0.54 | - | - | - |
| Sex (male vs. female) | 0.75 | 0.19–2.39 | 0.65 | - | - | - |
| Location (Ph vs. Pb,Pt) | 1.47 | 0.22–2.61 | 0.59 | - | - | - |
| Tumor size (> 30 mm vs. <30 mm) | 0.64 | 0.37–5.80 | 0.49 | - | - | - |
| CEA (> 3 U/mL vs. <3 U/mL) | 0.32 | 0.18–2.27 | 0.32 | - | - | - |
| CA19-9 (> 100 U/mL vs. <100 U/mL) | 0.62 | 0.15–1.88 | 0.45 | - | - | - |
| UR-M vs. UR-LA | 2.38 | 0.18–2.16 | 0.21 | - | - | - |
| CRT ((+) vs.(−)) | 8.06 | 0.61–9.24 | 0.002 | 8.54 | 2.03–35.97 | 0.004 |
| Tumor size (> 30 mm vs. <30 mm) | 0.77 | 2.15–30.18 | 0.68 | - | - | - |
| CEA > 3 U/mL vs. <3 U/mL) | 1.23 | 0.22–2.69 | 0.76 | - | - | - |
| CA19-9 (> 100 U/mL vs. <100 U/mL) | 0.35 | 0.32–4.80 | 0.32 | - | - | - |
| Change of tumor size (> 0.5 v.s. <0.5) | 0.72 | 0.04–2.74 | 0.61 | - | - | - |
| Change of CEA | 1.5 | 0.20–2.55 | 0.56 | - | - | -- |
| Change of CA19-9 | 1 | 0.39–5.83 | 1 | - | - | - |
| RECIST (PD,SD vs. PR,CR) | 4.93 | 0.12–7.91 | 0.015 | 5.05 | 1.20-21.25 | 0.03 |
| Period until operation (> 12 m vs. <12 m) | 0.89 | 1.37–17.72 | 0.86 | - | - | |
| Operation time (> 600 min vs. <600 min) | 1.36 | 0.26–3.09 0.39–4.70 |
0.63 | - | - | - |
| Bleeding volume (> 1000 mL vs. <1000 mL) | 0.89 | 0.23–3.52 | 0.87 | - | - | - |
| Evans (I-IIa vs. IIb-V) | 0.57 | 0.12–2.76 | 0.49 | - | - | - |
| pT (1,2 vs.3,4) | 2.14 | 0.55–8.31 | 0.27 | - | - | - |
| LN mets ((+) vs.(−)) | 0.77 | 0.16–3.67 | 0.75 | - | - | - |
| Adjuvant chemo. ((−) vs(+)) | 2.07 | 0.53–8.10 | 0.29 | - | - | - |
HR, hazard ratio; CI, confidential interval; Ph, pancreatic head; Pb, pancreatic body; Pt, pancreatic tail; UR-LA, unresectable locally advanced cancer; UR-M, unresectable cancer with metastasis; CRT, chemoradiotherapy; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; LN mets, lymph node metastasis.